ESMO Immuno-Oncology Congress 2021
Search results (14)
Biomarkers for immunotherapy: where are we?
The future is in the hands of tools built on combinations of biomarkers as no single biomarker is likely to reflect the complexity of the tumour microenvironment or account for tumour evolution
Trained immunity: a new promising oncology target?
In-depth understanding of immunological cellular mechanisms provides the basis to explore new ways to modulate the immune system for more effective treatment of cancer
Which biomarkers and how many should we use to improve outcomes with immunotherapy?
The complexity of identifying and clinically validating immunotherapy biomarkers can be addressed by broadening tumour sampling and expanding the characterisation methodologies used